Although the trial was terminated early due to poor recruitment, these findings suggest improved anti-tumour activity for tepotinib plus gefitinib compared to standard chemotherapy in patients with EGFR-mutant NSCLC and MET amplification. The gene discussed is MET; the disease is non-small cell lung carcinoma.